Publication | Closed Access

Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment

Neuro-oncologyRadiation OncologyTumor ImmunologyAnti-pd-1 ImmunotherapyCancer ImmunosurveillanceImmune Cell ModulationImmunologyTherapeutic VaccineImmune Checkpoint InhibitorHigh-grade GliomasCancer TreatmentImmunotherapyMedicineGliomaTumor Microenvironment